Objective: To investigate the connection of galectin 3 with HCC risk.
Methods: Publications were searched using PubMed, MEDLINE, EMBASE and the Chinese databases (including CNKI and WanFang) up to October 2015.
Results: A total of four studies were included into this analysis. The combined mean difference suggested that serum Galectin 3 levels tended to be associated with hepatitis 1.98(95% CI: 1.13-2.83, Z=4.57, P<0.00001) and healthy person 2.29(95% CI: 2.09-2.5, Z=21.78, P<0.00001).The serum Galectin3 level in HCC was significant higher than that in hepatitis and healthy person. The pooled sensitivity and specificity were 0.93 (95% CI: 0.86–0.97) and 0.83 (95% CI: 0.74–0.90), the pooled DOR were 116.78 (95% CI: 0.13–102122.46), the pooled positive LR were 12.71 (95% CI: 0.12–1374.27), and the pooled negative LR were 0.11 (95% CI: 0.00–12.51).
Conclusion: The serum Galectin 3 level of HCC is higher than that of hepatitis and healthy person. And the expression of serum Galectin 3 tended to be a bigger possibility biomarker for diagnosis of HCC.
Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.